Shandong Keyuan Pharmaceutical Co., Ltd. (SHE:301281)
China
· Delayed Price · Currency is CNY 37.89
-0.99 (-2.55%)
At close: Apr 29, 2026
SHE:301281 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 445.28 | 395.19 | 457.46 | 445.94 | 442.31 | 419.67 | Upgrade
|
| Other Revenue | 3.04 | 3.04 | 6.26 | 1.64 | 0.55 | 1.22 | Upgrade
|
| Revenue | 448.33 | 398.23 | 463.72 | 447.58 | 442.87 | 420.89 | Upgrade
|
| Revenue Growth (YoY) | 4.59% | -14.12% | 3.60% | 1.06% | 5.22% | 14.67% | Upgrade
|
| Cost of Revenue | 216.15 | 201.9 | 266.76 | 240.86 | 264.82 | 246.14 | Upgrade
|
| Gross Profit | 232.18 | 196.33 | 196.96 | 206.73 | 178.04 | 174.75 | Upgrade
|
| Selling, General & Admin | 155.48 | 131.53 | 116.12 | 99.72 | 56.03 | 63.1 | Upgrade
|
| Research & Development | 38.18 | 42.35 | 35.82 | 43.86 | 26.97 | 24.43 | Upgrade
|
| Other Operating Expenses | 0.78 | 2.55 | 4.19 | 4.36 | 5.3 | 4.47 | Upgrade
|
| Operating Expenses | 196.21 | 178.21 | 156.42 | 148.25 | 89.14 | 92.11 | Upgrade
|
| Operating Income | 35.97 | 18.12 | 40.54 | 58.48 | 88.91 | 82.64 | Upgrade
|
| Interest Expense | -0.02 | -0.02 | -0.04 | - | - | - | Upgrade
|
| Interest & Investment Income | 6.37 | 7.02 | 15.4 | 15.97 | 1.33 | 0.96 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.04 | 0.04 | -0.59 | 1.15 | 1.55 | -1.11 | Upgrade
|
| Other Non Operating Income (Expenses) | -9.29 | 0.07 | -2.03 | 0.09 | -0.32 | 0.05 | Upgrade
|
| EBT Excluding Unusual Items | 33.68 | 25.24 | 53.29 | 75.7 | 91.47 | 82.55 | Upgrade
|
| Impairment of Goodwill | -0.8 | -0.8 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.25 | -1.16 | 0.8 | 0.54 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.26 | -0.26 | -0.84 | 0.04 | 0.37 | -0.04 | Upgrade
|
| Asset Writedown | 0.7 | - | - | - | - | - | Upgrade
|
| Legal Settlements | -16.11 | -16.11 | -0.14 | - | - | - | Upgrade
|
| Other Unusual Items | 9.87 | 9.87 | 12.61 | 3.45 | 6.47 | 7.41 | Upgrade
|
| Pretax Income | 25.82 | 16.78 | 65.71 | 79.74 | 98.3 | 89.92 | Upgrade
|
| Income Tax Expense | 1.98 | 0.4 | 5.44 | 2.7 | 7.02 | 11.75 | Upgrade
|
| Earnings From Continuing Operations | 23.84 | 16.38 | 60.27 | 77.04 | 91.28 | 78.17 | Upgrade
|
| Minority Interest in Earnings | -0.3 | 0.18 | 0.18 | - | - | - | Upgrade
|
| Net Income | 23.54 | 16.55 | 60.45 | 77.04 | 91.28 | 78.17 | Upgrade
|
| Net Income to Common | 23.54 | 16.55 | 60.45 | 77.04 | 91.28 | 78.17 | Upgrade
|
| Net Income Growth | -62.04% | -72.62% | -21.54% | -15.60% | 16.77% | 13.87% | Upgrade
|
| Shares Outstanding (Basic) | 110 | 110 | 108 | 101 | 81 | 81 | Upgrade
|
| Shares Outstanding (Diluted) | 110 | 110 | 108 | 101 | 81 | 81 | Upgrade
|
| Shares Change (YoY) | 2.23% | 2.23% | 6.49% | 24.38% | 0.53% | -0.47% | Upgrade
|
| EPS (Basic) | 0.21 | 0.15 | 0.56 | 0.76 | 1.12 | 0.96 | Upgrade
|
| EPS (Diluted) | 0.21 | 0.15 | 0.56 | 0.76 | 1.12 | 0.96 | Upgrade
|
| EPS Growth | -62.87% | -73.21% | -26.32% | -32.14% | 16.15% | 14.40% | Upgrade
|
| Free Cash Flow | -53.15 | -93.58 | -356.9 | -33.12 | 84.75 | 31.83 | Upgrade
|
| Free Cash Flow Per Share | -0.48 | -0.85 | -3.31 | -0.33 | 1.04 | 0.39 | Upgrade
|
| Dividend Per Share | 0.050 | 0.050 | 0.200 | 0.300 | 0.286 | - | Upgrade
|
| Dividend Growth | -75.00% | -75.00% | -33.33% | 5.00% | - | - | Upgrade
|
| Gross Margin | 51.79% | 49.30% | 42.47% | 46.19% | 40.20% | 41.52% | Upgrade
|
| Operating Margin | 8.02% | 4.55% | 8.74% | 13.06% | 20.08% | 19.63% | Upgrade
|
| Profit Margin | 5.25% | 4.16% | 13.04% | 17.21% | 20.61% | 18.57% | Upgrade
|
| Free Cash Flow Margin | -11.86% | -23.50% | -76.96% | -7.40% | 19.14% | 7.56% | Upgrade
|
| EBITDA | 83.83 | 65.78 | 87.4 | 107.43 | 122.54 | 109.5 | Upgrade
|
| EBITDA Margin | 18.70% | 16.52% | 18.85% | 24.00% | 27.67% | 26.02% | Upgrade
|
| D&A For EBITDA | 47.87 | 47.67 | 46.86 | 48.95 | 33.63 | 26.86 | Upgrade
|
| EBIT | 35.97 | 18.12 | 40.54 | 58.48 | 88.91 | 82.64 | Upgrade
|
| EBIT Margin | 8.02% | 4.55% | 8.74% | 13.06% | 20.08% | 19.63% | Upgrade
|
| Effective Tax Rate | 7.66% | 2.39% | 8.27% | 3.38% | 7.14% | 13.06% | Upgrade
|
| Revenue as Reported | 398.23 | 398.23 | 463.72 | 447.58 | 442.87 | 420.89 | Upgrade
|
| Advertising Expenses | - | 4.09 | 4.03 | 1.89 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.